Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Phase II, Multicenter Study of Serplulimab Combined With CAPOX Plus Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer

NCT07819604 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT07819604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07819604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Phase II, Multicenter Study of Serplulimab Combined With CAPOX Plus Bevacizumab as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
Lead sponsor
Xijing Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2030
Enrollment
85 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced colorectal cancer